Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of XORTX THERAPEUTICS
No Price
Closing Price XTSX 28.04.2026:
3,69 CAD
29.04.2026 15:00
Current Prices from XORTX THERAPEUTICS
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ
XRTX
USD
29.04.2026 15:00
2,70 USD
-0,07 USD
-2,53 %
TSX-V
XRTX.V
CAD
28.04.2026 19:15
3,69 CAD
-0,27 CAD
-6,82 %
IEX
XRTX
USD
28.04.2026 19:13
2,82 USD
-0,15 USD
-5,05 %
Share Float & Liquidity
Free Float89,78 %
Shares Float250.023,00
Shares Outstanding278.488,00
Company Profile for XORTX THERAPEUTICS Share
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
